TY - JOUR
T1 - Development of two complementary LC–HRMS methods for analyzing sotatercept in dried blood spots for doping controls
AU - Lange, Tobias
AU - Walpurgis, Katja
AU - Thomas, Andreas
AU - Geyer, Hans
AU - Thevis, Mario
N1 - PMID: 31218901
PY - 2019/6/20
Y1 - 2019/6/20
N2 - Aim: sotatercept is a therapeutic Fc-fusion protein with erythropoiesis-stimulating activity. Due to a potential abuse of the drug by athletes in professional sports, a sensitive detection method is required. In sports drug testing, alternative matrices such as dried blood spots (DBS) are gaining increasing attention as they can provide several advantages over conventional matrices. Materials methods: Herein, two complementary LC–high-resolution mass spectrometry (HRMS) detection methods for sotatercept from DBS, an initial testing procedure (ITP) and a confirmation procedure (CP) were developed and validated for the first time. Both methods comprise an ultrasonication-assisted extraction, affinity enrichment, proteolytic digestion and HRMS detection. Results conclusion: For the multianalyte ITP, artificial samples fortified with sotatercept, luspatercept and bimagrumab, and authentic specimens containing bimagrumab were successfully analyzed as proof-of-concept. The validated detection methods for sotatercept are fit for purpose and the ITP was shown to be suitable for the detection of novel IgG-based pharmaceuticals in doping control DBS samples.
AB - Aim: sotatercept is a therapeutic Fc-fusion protein with erythropoiesis-stimulating activity. Due to a potential abuse of the drug by athletes in professional sports, a sensitive detection method is required. In sports drug testing, alternative matrices such as dried blood spots (DBS) are gaining increasing attention as they can provide several advantages over conventional matrices. Materials methods: Herein, two complementary LC–high-resolution mass spectrometry (HRMS) detection methods for sotatercept from DBS, an initial testing procedure (ITP) and a confirmation procedure (CP) were developed and validated for the first time. Both methods comprise an ultrasonication-assisted extraction, affinity enrichment, proteolytic digestion and HRMS detection. Results conclusion: For the multianalyte ITP, artificial samples fortified with sotatercept, luspatercept and bimagrumab, and authentic specimens containing bimagrumab were successfully analyzed as proof-of-concept. The validated detection methods for sotatercept are fit for purpose and the ITP was shown to be suitable for the detection of novel IgG-based pharmaceuticals in doping control DBS samples.
KW - Activin receptor type II (ActRII)
KW - LC-HRMS
KW - affinity purification
KW - doping
KW - dried blood spots
KW - proteolytic digestion
KW - sport
UR - https://www.mendeley.com/catalogue/df5b8262-fcb6-3144-b87d-92c19c29a306/
U2 - 10.4155/bio-2018-0313
DO - 10.4155/bio-2018-0313
M3 - Journal articles
SN - 1757-6180
VL - 11
SP - 923
EP - 940
JO - Bioanalysis
JF - Bioanalysis
IS - 10
ER -